Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Retatrutide - Eli Lilly and Company

Next Previous
Drug Profile

Retatrutide - Eli Lilly and Company

Alternative Names: GGG Tri-agonist - Eli Lilly and Company; GLP-1/GIP/glucagon tri-agonist - Eli Lilly and Company; LY-3437943

Latest Information Update: 15 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Class Analgesics; Antihyperglycaemics; Antirheumatics; Cardiovascular therapies; Obesity therapies; Peptides; Sleep disorder therapies
  • Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Back pain; Cardiovascular disorders; Obesity; Osteoarthritis; Sleep apnoea syndrome; Type 2 diabetes mellitus

Most Recent Events

  • 10 Sep 2025 Eli Lilly and Company plans a phase III SYNERGY-OUTCOMES trial for Non-alcoholic steatohepatitis in the US, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czech Republic, France, Germany, Hungary, India, Italy, Mexico, Romania, South Korea, Spain, Sweden, Taiwan, Ukraine, the UK (SC) (NCT07165028; CTIS2025-522674-36-00)
  • 26 Aug 2025 Eli Lilly and Company plans a phase I trial for Obesity in USA (SC) (NCT06313528)
  • 24 Jun 2025 Eli Lilly and Company plans a phase III TRIUMPH-7 trial for Obesity and Back pain in USA, Canada, Mexico, Argentina and Poland (SC) (NCT07035093)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top